Decision to list medical devices supplied by Stryker New Zealand Limited

Hospital devices

Decision

We are pleased to announce the approval of a listing agreement for the supply of medical devices to DHBs.

What we’re doing

We are pleased to announce the approval of a listing agreement with Stryker New Zealand Limited (“Stryker”) for the supply of:

In summary this will result in:

  • medical devices in the above-mentioned categories from Stryker being listed in Part III of Section H of the Pharmaceutical Schedule from 1 May under a national agreement that all DHBs may purchase under (“Agreement”); and
  • DHBs being able to continue to purchase other suppliers’ brands of beds and mattresses, operating tables and accessories, and rehabilitation products as the Agreement is not for sole supply.

Any changes to the original proposal?

This decision was subject to a consultation letter dated 18 February 2021.

During the consultation period the Agreement was amended to include additional terms relating to the purchasing models of the medical devices.

Who we think will be most interested

  • Suppliers and wholesalers
  • DHB staff
    • Clinical engineers, maintenance services and facilities staff
    • Clinical support staff
    • DHB loan store staff
    • DHB procurement and supply chain
    • Geriatricians
    • Neurologists and Neurosurgeons
    • Nurses
    • Occupational therapists
    • Orthopaedic surgeons
    • Orthotists
    • Paediatricians
    • Physiotherapists
    • Podiatrists
    • Rehabilitation physicians (including spinal units)
    • Speech-language therapists

Details about this decision

In 2018 PHARMAC issued a Request for Proposals (“RFP”) for supply of rehabilitation equipment, patient positioning products and supports.

The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

In coordination with PHARMAC, NZ Health Partnerships (“NZHP”) has previously released RFPs for ranges of medical devices which PHARMAC may list on the Pharmaceutical Schedule. NZHP released an RFP for beds and mattresses in December 2018 and operating tables and accessories in August 2019.

As a result of those processes Stryker and NZHP entered into agreements for beds and mattresses and operating tables and accessories.

In September 2020, PHARMAC released an ROI as an opportunity for suppliers to have operating tables and accessories considered for listing on the Pharmaceutical Schedule.

After completing the evaluation process and consulting on the provisional Agreement reached with Stryker, PHARMAC has decided to list Stryker’s rehabilitation products in Part III of Section H of the Pharmaceutical Schedule from 1 May 2021.

The Agreement between PHARMAC and Stryker for beds and mattresses, and operating tables and accessories was based on the agreements between NZHP and Stryker. As there were no material changes made to the terms and conditions that are currently in place PHARMAC decided that consultation on the provisional Agreement was not required, and has decided to list beds and mattresses, and operating tables and accessories in Part III of Section H of the Pharmaceutical Schedule from 1 May 2021.

The list of products will be available on PHARMAC's website from 1 May 2021, in both PDF and Excel formats.

DHBs can continue to choose which beds and mattresses, operating tables and accessories, and rehabilitation products they purchase, including those from other suppliers. DHBs that purchase these products from Stryker must do so under the terms and conditions, including pricing, in the PHARMAC Agreement from 1 May 2021.

The Agreement includes terms and conditions for training and education to be provided by Stryker on the appropriate use of its beds and mattresses, operating tables and accessories, and rehabilitation products which is to be provided at times and in formats as agreed with individual DHBs.

Our response to what you told us

We appreciate the time people took to respond to this consultation.

All consultation responses received by 11 March 2021 were considered in their entirety in making the decision to list medical devices supplied by Stryker.

A summary of the main themes raised in feedback and our responses to the feedback are set out below:

Theme

Comment

No technical or resource impacts anticipated as a result of the proposal.

Noted.

Support for listing the medical devices and that the agreement is not for sole supply.

Noted.

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.